Rabbit anti-Human CDKN2AIP Polyclonal Antibody | anti-CDKN2AIP antibody

CDKN2AIP (CDKN2A-interacting Protein, Collaborator of ARF, CARF, FLJ20036) (PE)

Cat. Num. AAA6373597

• Gene Names: CDKN2AIP; CARF
• Reactivity: Human
• Applications: Western Blot
• Purity: Purified by Protein A Affinity Chromatography.
• Synonyms: CDKN2AIP; Polyclonal Antibody; CDKN2AIP (CDKN2A-interacting Protein; Collaborator of ARF; CARF; FLJ20036) (PE); anti-CDKN2AIP antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes human CDKN2AIP.
• Purity/Purification: Purified by Protein A Affinity Chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with R-Phycoerythrin (PE).
• Sequence Length: 2578

• Applicable Applications for anti-CDKN2AIP antibody: Western Blot (WB)
• Application Notes: Applications are based on unconjugated antibody.
• Immunogen: Full length human CDKN2AIP, aa1-579 (AAH22270.1).
• Immunogen Sequence: MAQEVSEYLSQNPRVAAWVEALRCDGETDKHWRHRRDFLLRNAGDLAPAGGAASASTDEAADAESGTRNRQLQQLISFSMAWANHVFLGCRYPQKVMDKILSMAEGIKVTDAPTYTTRDELVAKVKKRGISSSNEGVEEPSKKRVIEGKNSSAVEQDHAKTSAKTERASAQQENSSTCIGSAIKSESGNSARSSGISSQNSSTSDGDRSVSSQSSSSVSSQVTTAGSGKASEAEAPDKHGSSFVSLLKSSVNSHMTQSTDSRQQSGSPKKSALEGSSASASQSSSEIEVPLLGSSGSSEVELPLLSSKPSSETASSGLTSKTSSEASVSSSVAKNSSSSGTSLLTPKSSSSTNTSLLTSKSTSQVAASLLASKSSSQTSGSLVSKSTSLASVSQLASKSSSQTSTSQLPSKSTSQSSESSVKFSCKLTNEDVKQKQPFFNRLYKTVAWKLVAVGGFSPNVNHGELLNAAIEALKATLDVFFVPLKELADLPQNKSSQESIVCELRCKSVYLGTGCGKSKENAKAVASREALKLFLKKKVVVKICKRKYRGSEIEDLVLLDEESRPVNLPPALKHPQELL
• Conjugate: PE
• Note: Preservative Free
• Preparation and Storage: Store product at 4 degree C in the dark. DO NOT FREEZE! Stable at 4 degree C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: PE conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Western Blot (WB)

(Western Blot analysis of CDKN2AIP expression in transfected 293T cell line by CDKN2AIP polyclonal antibody. Lane 1: CDKN2AIP transfected lysate (61.1kD). Lane 2: Non-transfected lysate.)

Related Product Information for anti-CDKN2AIP antibody

Activates p53/TP53 by CDKN2A-dependent and CDKN2A-independent pathways.

Product Categories/Family for anti-CDKN2AIP antibody

Antibodies; Protein Kinase Inhibitors

NCBI and Uniprot Product Information

• NCBI GI #: 18490354
• NCBI GeneID: 55602
• UniProt Accession #: Q8N726; Q9NXV6
• NCBI Official Full Name: Homo sapiens CDKN2A interacting protein, mRNA
• NCBI Official Synonym Full Names: CDKN2A interacting protein
• NCBI Official Symbol: CDKN2AIP
• NCBI Official Synonym Symbols: CARF
• NCBI Protein Information: CDKN2A-interacting protein
• UniProt Protein Name: Cyclin-dependent kinase inhibitor 2A, isoform 4
• Protein Family: CDKN2A-interacting protein
• UniProt Gene Name: CDKN2A
• UniProt Synonym Gene Names: CDKN2; MLM
• UniProt Entry Name: CD2A2_HUMAN

NCBI Description

The protein encoded by this gene regulates the DNA damage response through several different signaling pathways. One such pathway is the p53-HDM2-p21(WAF1) pathway, which is critical to the DNA damage response. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]

Uniprot Description

p16-INK4A iso4: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Nucleolus; Cell cycle regulation; Tumor suppressor

Chromosomal Location of Human Ortholog: 9p21

Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; nucleus; cytosol

Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor binding; protein kinase binding

Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; negative regulation of immature T cell proliferation in the thymus; caspase activation; protein destabilization; transcription, DNA-dependent; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of protein kinase activity; negative regulation of phosphorylation; positive regulation of transcription from RNA polymerase II promoter; mitotic cell cycle; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Li-fraumeni Syndrome 1; Melanoma-pancreatic Cancer Syndrome